Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain

Future Cardiol. 2018 May;14(3s):3-8. doi: 10.2217/fca-2018-0020.

Abstract

Aim: To analyze the clinical profile and rates of stroke, major bleeding and intracranial hemorrhage of patients with atrial fibrillation (AF) treated with rivaroxaban in clinical practice.

Methods: Retrospective study of AF patients anticoagulated with rivaroxaban in a Healthcare Area of Valencia, Spain. Patients started treatment with rivaroxaban from July 2012 to December 2015.

Results: A total of 230 patients (mean age 76.9 ± 9.9 years; CHA2DS2-VASc 4.3 ± 1.7; HAS-BLED 1.7 ± 0.9) were included. Rates of stroke, major bleeding and intracranial bleeding were 0.4, 1.9 and 0.5 events per 100 patient-years, respectively.

Conclusion: In this cohort of AF patients anticoagulated with rivaroxaban, despite patients being older and having a high thromboembolic risk, rates of stroke, major bleeding and intracranial bleeding were low.

Keywords: atrial fibrillation; effectiveness; rivaroxaban; routine practice; safety.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy*
  • Factor Xa Inhibitors / therapeutic use*
  • Female
  • Hemorrhage / epidemiology
  • Humans
  • Male
  • Practice Patterns, Physicians'
  • Retrospective Studies
  • Risk Factors
  • Rivaroxaban / therapeutic use*
  • Spain
  • Stroke / etiology
  • Stroke / prevention & control*

Substances

  • Factor Xa Inhibitors
  • Rivaroxaban